Showing 1341-1350 of 1635 results for "".
- Ciliatech Presents New Concept in Glaucoma Implants, First to Bypass Opening Anterior Eye Chamberhttps://modernod.com/news/ciliatech-presents-new-concept-in-glaucoma-implants-first-to-bypass-opening-anterior-eye-chamber/2481085/Ciliatech, which is developing a new class of implant to treat glaucoma durably named
- Trukera Medical Launches ScoutPro Osmolarity Systemhttps://modernod.com/news/trukera-medical-launches-new-scoutpro-osmolarity-system/2481081/Trukera Medical unveiled the first product under the new company name, the ScoutPro Osmolarity System. Designed to help advance corneal health decisions for busy eye care practices, ScoutPro is the first and only portable osmometer in the United States. The launch comes a wee
- NIH Researchers Develop Gene Therapy for Rare Ciliopathyhttps://modernod.com/news/nih-researchers-develop-gene-therapy-for-rare-ciliopathy/2481074/Researchers from the National Eye Institute (NEI) have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness in early childhood. Using patient-derived retina organoids (also known as retinas-in-
- Himalayan Cataract Project Appoints Katherine G. Overbey as CEOhttps://modernod.com/news/himalayan-cataract-project-appoints-katherine-g-overbey-as-ceo/2481070/The Himalayan Cataract Project (HCP) has named Katherine G. Overbey (K-T) its new Chief Executive Officer, effective as of October 4, 2022. As HCP enters its 28th year, HCP’s Board of Directors anticipates that Ms. Overbey will guide the organization in its mission to c
- First US Patient Receives Autologous Stem Cell Therapy to Treat Dry AMDhttps://modernod.com/news/first-us-patient-receives-autologous-stem-cell-therapy-to-treat-dry-amd/2481061/At the National Institutes of Health, a surgical team successfully implanted a patch of tissue made from patient cells with the goal of treating advanced dry age-related macular degeneration (AMD), also known as geographic atrophy. The patient received the therapy as part of
- Oyster Point's Tyrvaya To Be Covered By the Largest Medicare Pharmacy Benefit Managerhttps://modernod.com/news/oyster-point-pharma-announces-tyrvana-to-be-covered-by-the-largest-medicare-pharmacy-benefit-manager/2481032/Oyster Point Pharma announced that the largest Medicare Pharmacy Benefit Manager in the United States will add Tyrvaya Nasal Spray on its Medicare Part D formularies, effective September 1, 2022. “We are excited to announce this important milestone which will further expand p
- CooperVision MiSight 1 Day Officially Launches in Chinahttps://modernod.com/news/coopervision-misight-1-day-officially-launches-in-china/2481026/CooperVision and EssilorLuxottica have officially launched MiSight 1 day contact lenses in China, marking its availability in the world’s largest country for myopia management. It is the first product of any type that has an indication from the Chinese National Medical Products Adminis
- Research to Prevent Blindness and the American Academy of Ophthalmology Award New Research Grants to Improve Eye Carehttps://modernod.com/news/research-to-prevent-blindness-and-the-american-academy-of-ophthalmology-award-new-research-grants-to-improve-eye-care/2481025/The American Academy of Ophthalmology and Research to Prevent Blindness (RPB) announced the 2022 recipients of the RPB/AAO Award for IRIS Registry Research. The researchers will use the IRIS Registry—the nation’s first and largest comprehensive eye disease clinical registry—to c
- High-Tech Imaging Reveals Details About Rare Eye Disorderhttps://modernod.com/news/high-tech-imaging-reveals-details-about-rare-eye-disorder/2481022/Using a new imaging technique, researchers from the National Eye Institute (NEI) have determined that retinal lesions from vitelliform macular dystrophy (VMD) vary by gene mutation. Addressing these differences may be key in designing effective treatments for this and other rare diseases, accordi
- Second Sight Medical Products Announces Year 4 NIH Funding of its Orion Studyhttps://modernod.com/news/second-sight-medical-products-announces-year-4-nih-funding-of-its-orion-study/2480982/Second Sight Medical Products announced that the company received notice from the National Institutes of Health (NIH) of the release of year 4 funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (Orion Trial), grant 5UH3NS103442. The NIH released&n